{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:02:35Z","timestamp":1793318555027,"version":"4.5.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vaccination guidelines for recipients of blood and marrow transplantation (BMT) have been published by 3 major societies: American Blood and Marrow Transplantation, European Group of Blood and Marrow Transplantation, and Infectious Disease Society of America. Despite these extensive review articles, clinicians caring for BMT recipients continue to field frequently asked questions (FAQs) regarding the \u201cwho, when, and how\u201d of feasible and effective posttransplant vaccination, frequently in the absence of adequate data. This may reflect discomfort with a \u201cone size fits all\u201d policy that makes no adjustments for different posttransplant clinical scenarios. Existing guidelines also lack practical dose clarifications when administering vaccines to patients who differ by age, underlying diagnosis, or amount of immunosuppressive therapy. Frequently, little or conflicting guidance is given regarding age-related schedules for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis; and human papillomavirus vaccines) in addition to time posttransplant or other factors. FAQs and their answers form the body of this article and are shared with readers as a concise practical review, with the intent to facilitate good clinical practice.<\/jats:p>","DOI":"10.1182\/blood-2015-12-550475","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:06:16Z","timestamp":1459901176000},"page":"2824-2832","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":122,"title":["How I vaccinate blood and marrow transplant recipients"],"prefix":"10.1182","volume":"127","author":[{"given":"Paul A.","family":"Carpenter","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Pediatrics, University of Washington, Seattle, WA; and"},{"name":"Seattle Children\u2019s Hospital, Seattle WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Englund","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington, Seattle, WA; and"},{"name":"Seattle Children\u2019s Hospital, Seattle WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111902105713100_B1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2009.263","article-title":"Vaccination of hematopoietic cell transplant recipients.","volume":"44","author":"Ljungman","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111902105713100_B2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in Biol Blood Marrow Transplant. 2010;16(2):294].","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111902105713100_B3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2019111902105713100_B4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbmt.2004.12.330","article-title":"Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation.","volume":"11","author":"Antin","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111902105713100_B5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/bmt.2009.364","article-title":"Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant.","volume":"45","author":"Cordonnier","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2019111902105713100_B6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.vaccine.2011.02.018","article-title":"Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD.","volume":"29","author":"Hilgendorf","year":"2011","journal-title":"Vaccine"},{"key":"2019111902105713100_B7","unstructured":"Kroger\n              AT\n            \n            \n              Strikas\n              RA\n            \n          \n          General recommendations for vaccination & immunoprophylaxis. http:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2016\/the-pre-travel-consultation\/general-recommendations-for-vaccination-immunoprophylaxis. Accessed April 17, 2016"},{"key":"2019111902105713100_B8","unstructured":"Kroger\n              AT\n            \n            \n              Sumaya\n              CV\n            \n            \n              Pickering\n              LK\n            \n            \n              Atkinson\n              WL\n            \n          \n          Table 4: guidelines for administering antibody-containing products and vaccines. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6002a1.htm#Tab4. Accessed April 17, 2016"},{"issue":"6","key":"2019111902105713100_B9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007890-197312000-00015","article-title":"Studies of immunological reactivity following syngeneic or allogeneic marrow grafts in man.","volume":"16","author":"Fass","year":"1973","journal-title":"Transplantation"},{"issue":"6","key":"2019111902105713100_B10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/517952","article-title":"Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient.","volume":"28","author":"Kamboj","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"2019111902105713100_B11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1086\/314869","article-title":"A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization.","volume":"180","author":"Keitel","year":"1999","journal-title":"J Infect Dis"},{"issue":"11","key":"2019111902105713100_B12","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices.","volume":"64","author":"Petrosky","year":"2015","journal-title":"Morb Mortal Wkly Rep"},{"issue":"17","key":"2019111902105713100_B13","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"2019111902105713100_B14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/bmt.2008.264","article-title":"Influenza vaccination in hematopoietic SCT recipients.","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111902105713100_B15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2012.08.015","article-title":"A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation.","volume":"19","author":"Karras","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111902105713100_B16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults.","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"2019111902105713100_B17","unstructured":"Advisory Committee on Immunization Practices (ACIP). ACIP presentation slides: June 2015 meeting. http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2015-06.html. Accessed April 17, 2016"},{"issue":"1","key":"2019111902105713100_B18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbmt.2011.07.027","article-title":"Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.","volume":"18","author":"Mahler","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111902105713100_B19","unstructured":"World Health Organization. Measles fact sheet. http:\/\/www.who.int\/mediacentre\/factsheets\/fs286\/en\/. Accessed April 17, 2016"},{"issue":"4","key":"2019111902105713100_B20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/159.4.610","article-title":"Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.","volume":"159","author":"Ljungman","year":"1989","journal-title":"J Infect Dis"},{"issue":"10","key":"2019111902105713100_B21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1086\/598324","article-title":"Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2019111902105713100_B22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/cid\/civ287","article-title":"Immunogenicity, safety, and tolerability of 13-valent pneumococcal ;conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged \u22652 years: an open-label study.","volume":"61","author":"Cordonnier","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2019111902105713100_B23","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.2105\/AJPH.2014.302425","article-title":"The influence of provider communication behaviors on parental vaccine acceptance and visit experience.","volume":"105","author":"Opel","year":"2015","journal-title":"Am J Public Health"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/23\/2824\/1394068\/2824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/23\/2824\/1394068\/2824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:11:20Z","timestamp":1574129480000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/23\/2824\/35292\/How-I-vaccinate-blood-and-marrow-transplant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,9]]},"references-count":23,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-12-550475","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,9]]}}}